“中国特应性皮炎互联网社交媒体患者教育模式对疾病预后和生活质量的影响”患者教育项目成功启动

2020-06-11 MedSci原创 MedSci原创

该项目旨在通过互联网社交媒体渠道,进行患者教育,改善患者疾病预后和生活质量,最终使患者获益。

   2020年6月7日,由北京医学奖励基金会发起、重庆医科大学附属儿童医院王华教授牵头、迈蓝医药资助、梅斯医学提供学术支持的《中国特应性皮炎互联网社交媒体患者教育模式对疾病预后和生活质量的影响》患教项目通过线上会议形式正式启动,该项目旨在通过互联网社交媒体渠道,进行患者教育,改善患者疾病预后和生活质量,最终使患者获益。

    参加此次项目启动会的单位及专家有重庆医科大学附属儿童医院王华教授、首都医科大学附属北京儿童医院马琳教授、广州市妇女儿童医疗中心陈谨萍教授、深圳市儿童医院李萍教授、湖南省儿童医院汤建萍教授、苏州大学附属儿童医院钱华教授、复旦大学附属儿科医院王榴慧教授、天津市儿童医院李钦峰教授、昆明市儿童医院舒虹教授、浙江大学医学院附属儿童医院李云玲教授、中国医科大学附属盛京医院韩秀萍教授、西安市儿童医院陈曦教授等12家全国优秀儿科诊疗中心主任以及各中心负责的临床医生。

    会议由重庆医科大学附属儿童医院王华教授主持。王华教授指出,特应性皮炎(Atopic dermatitis, AD)是一种慢性复发性炎症性皮肤病,其发病率逐年升高且发病机制复杂,诱因繁多,仅仅依靠药物治疗对AD的疗效是有限的。患者教育有助于减轻AD严重程度,改善生活质量。此次联合全国12家优秀儿童诊疗中心,共同发起“中国特应性皮炎互联网社交媒体患者教育模式对疾病预后和生活质量的影响”项目,期望通过合适的患教方式提高患者生活质量。

  来自重庆医科大学附属儿童医院杨欢博士对整体项目进行了介绍,从项目出发点和背景对项目可行性和具体方案做了很详细的阐释。之后,作为本项目全程学术及技术支持方,梅斯医学项目负责人向所有中心详细介绍了项目操作流程及在线演示。

接下来讨论环节,每家中心纷纷对项目内容提出了宝贵意见,线上讨论气氛热烈,针对每条意见都进行了充分的讨论和决策,最终项目所有问题都达成了共识,各中心对此项目均表示全力的支持和配合。

    最后,王华教授做会议总结,通过此次启动会,明确了项目的目的和流程,再次感谢北京医学奖励基金会发起、迈蓝医药的资助以及梅斯医学的服务支持,特别感谢12家中心单位的全力配合,“中国特应性皮炎互联网社交媒体患者教育模式对疾病预后和生活质量的影响”项目启动会圆满结束,希望早日获得预期结果。

王华教授,主任医师,重庆医科大学儿童医院皮肤科主任,小儿皮肤病学教研室主任,国家三级教授,博士,博士研究生导师。

中华医学儿科学分会皮肤病学组副组长

中国医师协会皮肤科医师分会儿童皮肤病专业委员会主任委员

重庆市皮肤性病专委会副主任委员

重庆市变态反应专委会副主仼委员

《儿科药学杂志》常务编委,Pediatric Allergy and Immunology杂志编委,《中华皮肤科杂志》等审稿专家。

从事小儿皮肤病临床医疗、教学及科研工作30余年,有丰富的临床工作经验。曾留学德国波恩大学医学院,从事变态反应临床和特应性皮炎的基础研究工作。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1739328, encodeId=ce361e3932825, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Sep 25 13:26:52 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274319, encodeId=e2c712e431901, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603448, encodeId=643c160344876, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604288, encodeId=c88f16042887b, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1739328, encodeId=ce361e3932825, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Sep 25 13:26:52 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274319, encodeId=e2c712e431901, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603448, encodeId=643c160344876, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604288, encodeId=c88f16042887b, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1739328, encodeId=ce361e3932825, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Sep 25 13:26:52 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274319, encodeId=e2c712e431901, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603448, encodeId=643c160344876, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604288, encodeId=c88f16042887b, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=)]
    2020-06-13 fengyi818
  4. [GetPortalCommentsPageByObjectIdResponse(id=1739328, encodeId=ce361e3932825, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Sep 25 13:26:52 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274319, encodeId=e2c712e431901, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603448, encodeId=643c160344876, content=<a href='/topic/show?id=657ce391325' target=_blank style='color:#2F92EE;'>#社交#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73913, encryptionId=657ce391325, topicName=社交)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=004519034290, createdName=fengyi818, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604288, encodeId=c88f16042887b, content=<a href='/topic/show?id=30d85304427' target=_blank style='color:#2F92EE;'>#患者教育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53044, encryptionId=30d85304427, topicName=患者教育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843819174030, createdName=xue8608, createdTime=Sat Jun 13 05:26:52 CST 2020, time=2020-06-13, status=1, ipAttribution=)]